StockTipsArenaBeta

BUY Cohance Lifesciences Limited — Mehul Kothari, Anand Rathi

BUYCohance Lifesciences Limited
Cohance Lifesciences share price target & all analyst calls

byMehul Kothari, Anand RathiHorizon: 1–3 months20 Aug 2026via Zee Business (Live)

Entry₹477.8Inferred
Target₹550
Total upside +15.11% (call closed)
Stop loss₹435-8.96% risk
Exit₹43511 Sept 2026, 12:09 pm
Stop-loss hit-8.96%
Follow Mehul Kothari for new calls(16% target hit, 38 closed calls)Get alertsWatch COHANCE for new buy/sell callsGet alertsSee 1 active Short-term call on COHANCESee 39 active Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 11 Sept 2026
6 supporting3 neutral3 opposing
Supports the BUY call (6)

Cohance Lifesciences to invest $18 million in NJ Bio, Aruka Bio to deepen ADC push

NewsCnbc-Tv18·3 Sept · 1w ago

(opens in new tab)

Cohance Lifesciences announced two transactions to strengthen its Antibody-drug Conjugate (ADC) strategy: an investment of USD 13 million in NJ Bio and a controlling investment of USD 5 million in Aru

BSE · Company Update·3 Sept · 1w ago

(opens in new tab)

Cohance Lifesciences announced two proposed transactions to strengthen its Antibody-drug Conjugate (ADC) strategy: an additional investment of USD 13 million in NJ Bio and a controlling investment of

NSE · Press Release·3 Sept · 1w ago

(opens in new tab)

1 other SEBI-registered advisor has an active short-term BUY call on this stock

Advisor consensus · same horizon·18 Aug · 3w ago

2 advisors have active long-term BUY calls on this stock

Advisor consensus · adjacent horizon·6 Aug · 1mo ago

Neutral / worth noting (3)

Nothing found in this tip’s window yet.

Weighs against the BUY call (3)

Cohance Life receives form 483 with 4 observations from USFDA for FDF plant in Telangana

NewsCnbc-Tv18·5 Sept · 6d ago

(opens in new tab)

1 advisor has an active long-term SELL call on this stock

Advisor consensus · adjacent horizon·6 Aug · 1mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Cohance Lifesciences

All analyst calls on Cohance Lifesciences

More from Mehul Kothari, Anand Rathi

Every call and its outcome